GAITHERSBURG, Md.--(BUSINESS WIRE)--March 7, 2006--GenVec, Inc. (Nasdaq:GNVC) announced today the completion of enrollment in the company's follow-on Phase I study of its AdPEDF gene therapy in patients diagnosed recently with wet age-related macular degeneration (AMD). This 9-center clinical trial involves 20 patients who received a single injection of one of two doses of AdPEDF. Study participants will be evaluated at three and twelve weeks to assess changes in their vision and to confirm the drug's safety profile and will then be followed for one year after treatment. The trial includes several patients with refractory wet AMD who were treated previously with approved therapies but continued to lose vision, a problem in more than two-thirds of patients with AMD who receive treatment with anti-VEGF or photodynamic therapies.
